Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting (Tables)

6 Months Ended

Jan. 31, 2024

The following financial information represents the operating results of the reportable segments of the Company:

	Products		Corporate & Other			Consolidated
Revenues	$	8,553		—		$	8,553

Operating costs and expenses:
Cost of revenues		4,329		—			4,329
Research and development		578	$	2			580
Selling, general and administrative		3,284		1,784			5,068
Legal and related expenses		22		739			761
Total operating costs and expenses		8,213		2,525			10,738

Operating income (loss)		340		(2,525	)		(2,185	)

Other income (expense)
Interest		34		859			893
Change in fair value of convertible debentures		—		(383	)		(383	)
Other		2		117			119
Foreign exchange gain		693		—			693
Income (loss) before taxes	$	1,069	$	(1,932	)	$	(863	)

Depreciation and amortization included above	$	172	$	95		$	267

Share-based compensation included above:
Selling, general and administrative		42		207			249
Cost of sales		12		—			12
Total	$	54	$	207		$	261

Capital expenditures	$	—	$	27		$	27

	Products			Corporate & Other			Consolidated
Revenues	$	7,514			—		$	7,514

Operating costs and expenses:
Cost of revenues		4,616			—			4,616
Research and development		1,113		$	12			1,125
Selling, general and administrative		3,036			2,394			5,430
Legal and related expenses		11			877			888
Total operating costs and expenses		8,776			3,283			12,059

Operating loss		(1,262	)		(3,283	)		(4,545	)

Other income (expense)
Interest		29			34			63
Other		2			116			118
Foreign exchange gain		1,472			—			1,472
Income (loss) before taxes	$	241		$	(3,133	)	$	(2,892	)

Depreciation and amortization included above	$	171		$	91		$	262

Share-based compensation included above:
Selling, general and administrative		20			409			429
Cost of sales		6			—			6
Total	$	26		$	409		$	435

Capital expenditures	$	632		$	41		$	673

	Products			Corporate & Other			Consolidated
Revenues	$	16,359			—		$	16,359

Operating costs and expenses:
Cost of revenues		8,680			—			8,680
Research and development		1,416		$	13			1,429
Selling, general and administrative		6,383			5,687			12,070
Legal and related expenses		51			1,784			1,835
Total operating costs and expenses		16,530			7,484			24,014

Operating loss		(171	)		(7,484	)		(7,655	)

Other income (expense)
Interest		68			1,802			1,870
Change in fair value of convertible debentures		—			(711	)		(711	)
Other		3			273			276
Foreign exchange loss		(318	)		—			(318	)
Loss before taxes	$	(418	)	$	(6,120	)	$	(6,538	)

Depreciation and amortization included above	$	338		$	199		$	537

Share-based compensation included above:
Selling, general and administrative		65			1,254			1,319
Cost of sales		17			—			17
Total	$	82		$	1,254		$	1,336

Capital expenditures	$	246		$	33		$	279

	Products			Corporate & Other			Consolidated
Revenues	$	14,617			—		$	14,617

Operating costs and expenses:
Cost of revenues		9,205			—			9,205
Research and development		1,803		$	21			1,824
Selling, general and administrative		5,920			4,946			10,866
Legal and related expenses		36			1,859			1,895
Total operating costs and expenses		16,964			6,826			23,790

Operating loss		(2,347	)		(6,826	)		(9,173	)

Other income (expense)
Interest		54			81			135
Other		4			114			118
Foreign exchange gain		675			—			675
Income (loss) before taxes	$	(1,614	)	$	(6,631	)	$	(8,245	)

Depreciation and amortization included above	$	336		$	174		$	510

Share-based compensation included above:
Selling, general and administrative		40			749			789
Cost of sales		11			—			11
Total	$	51		$	749		$	800

Capital expenditures	$	938		$	224		$	1,162